The vitamin D receptor in osteoblastic cells but not secreted parathyroid hormone is crucial for soft tissue calcification induced by the proresorptive activity of 1,25(OH)2D3

[1]  J. Uitto,et al.  Weighing the Evidence for the Roles of Plasma Versus Local Pyrophosphate in Ectopic Calcification Disorders , 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  Hideaki E. Kato,et al.  Endogenous ligand recognition and structural transition of a human PTH receptor. , 2022, Molecular cell.

[3]  Chun-Yuan Chen,et al.  Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox , 2022, Nature Communications.

[4]  R. Fatica,et al.  Extraosseous calcification in kidney disease , 2022, Cleveland Clinic Journal of Medicine.

[5]  G. Carmeliet,et al.  Integrated View on the Role of Vitamin D Actions on Bone and Growth Plate Homeostasis , 2021, JBMR plus.

[6]  G. Atkins,et al.  Vitamin D receptor expression in mature osteoclasts reduces bone loss due to low dietary calcium intake in male mice , 2021, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  T. Martin,et al.  Physiological and Pharmacological Roles of PTH and PTHrP in Bone using their Shared Receptor, PTH1R. , 2021, Endocrine reviews.

[8]  K. Tsuchiya,et al.  Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis , 2020, Kidney international reports.

[9]  Yoko Yamamoto,et al.  The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo , 2020, Endocrinology.

[10]  C-L Chen,et al.  Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study , 2020, Osteoporosis International.

[11]  G. Carmeliet,et al.  Vdr expression in osteoclast precursors is not critical in bone homeostasis , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  D. Goltzman,et al.  Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification. , 2019, JCI insight.

[13]  John H. White,et al.  Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions , 2018, Endocrine reviews.

[14]  N. Udagawa,et al.  Mechanisms involved in bone resorption regulated by vitamin D , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  H. Morris,et al.  Absence of vitamin D receptor in mature osteoclasts results in altered osteoclastic activity and bone loss , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  J. Fleet.  The role of vitamin D in the endocrinology controlling calcium homeostasis , 2017, Molecular and Cellular Endocrinology.

[17]  Takashi Nakamura,et al.  VDR in Osteoblast‐Lineage Cells Primarily Mediates Vitamin D Treatment‐Induced Increase in Bone Mass by Suppressing Bone Resorption , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  R. Kumar,et al.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. , 2016, Endocrine reviews.

[19]  J. Bilezikian,et al.  Parathyroid hormone: anabolic and catabolic actions on the skeleton. , 2015, Current opinion in pharmacology.

[20]  G. Mazziotti,et al.  Parathyroid hormone pulsatility: physiological and clinical aspects , 2015, Bone Research.

[21]  B. Lanske,et al.  FGF23 promotes renal calcium reabsorption through the TRPV5 channel , 2014, The EMBO journal.

[22]  P. Chambon,et al.  Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. , 2013, Endocrinology.

[23]  D. Towler,et al.  Arterial calcification and bone physiology: role of the bone–vascular axis , 2012, Nature Reviews Endocrinology.

[24]  J. Schrooten,et al.  Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. , 2012, The Journal of clinical investigation.

[25]  T. Mizoguchi,et al.  Daily administration of eldecalcitol (ED‐71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  Jason R. Stubbs,et al.  Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  T. Sone,et al.  A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. , 2011, Bone.

[28]  C. Shanahan,et al.  Arterial Calcification in Chronic Kidney Disease: Key Roles for Calcium and Phosphate , 2011, Circulation research.

[29]  Sakae Tanaka,et al.  Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor-κB Ligand-neutralizing Antibody , 2011, The Journal of Biological Chemistry.

[30]  J. Voelz,et al.  Chapter 20 , 2009, Wide Neighborhoods.

[31]  V. Persy,et al.  Vascular calcification and bone disease: the calcification paradox. , 2009, Trends in molecular medicine.

[32]  P. Carmeliet,et al.  Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. , 2006, The Journal of clinical investigation.

[33]  A. McMahon,et al.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors , 2006, Development.

[34]  S. Cummings,et al.  Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[36]  M. Inaba,et al.  Primary Hyperparathyroidism With Multiple Osteosclerotic Lesions of the Calvarium , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  P. Price,et al.  Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[38]  P. Schauerte,et al.  PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. , 2001, The American journal of pathology.

[39]  P. Price,et al.  Warfarin-induced artery calcification is accelerated by growth and vitamin D. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Millán,et al.  Alkaline Phosphatase Knock‐Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[42]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  R. Behringer,et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.

[44]  I. Macintyre.  Vitamin D metabolism. , 1973, The New England journal of medicine.

[45]  N. Udagawa,et al.  Osteoclastogenesis and Vitamin D , 2018 .

[46]  C. Marcocci,et al.  Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis. , 2018, Frontiers of hormone research.

[47]  W. C. O'Neill,et al.  Targeting serum calcium in chronic kidney disease and end-stage renal disease: is normal too high? , 2016, Kidney international.

[48]  P. Dhawan,et al.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. , 2016, Physiological reviews.

[49]  S. Moncada.  Physiological and clinical aspects , 1992 .

[50]  S. K. Lee,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with , 2022 .

[51]  R. L. Cain,et al.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. , 2001, Endocrinology.